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replacement. However, there are studies that report
improved survival with large prosthetic valves compared
with small ones, and this might be due to less initial hyper-
trophy or a more pronounced reduction in LV mass.3,4
The regression in LV mass is likely to be influenced
by the prosthetic valve type and size. A regression in LV
mass after aortic valve replacement has been docu-
mented,5-7 but only a few studies describe the impact of
valve size.5,6 One recent report on the importance of
prosthetic type (stented and stentless biologic valves vs
bileaflet mechanical valves) did not find any statistical-
ly significant differences in regression of LV mass, but
the number of patients studied was small.8
The aims of the present study were to evaluate the
effects of valve replacement per se and of valve type
(mechanical or biologic) and size on postoperative LV
mass and LV systolic and diastolic function.
Patients and methods
Study patients. Between January 1991 and August 1993, a
representative previously described population of 239 patients
L eft ventricular (LV) hypertrophy is a known predic-tor of morbid events in asymptomatic hypertensive
patients or otherwise healthy adults.1 In a study of
patients with severe aortic stenosis, we found increased
risk for early mortality among those with a small hyper-
trophic heart and narrow LV outflow tract.2 We are not
aware of any study that documents the late prognostic
importance of preoperative LV hypertrophy in aortic valve
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INFLUENCE OF AORTIC VALVE REPLACEMENT, PROSTHESIS TYPE, AND SIZE ON FUNCTIONAL
OUTCOME AND VENTRICULAR MASS IN PATIENTS WITH AORTIC STENOSIS
underwent aortic valve replacement involving 3 different
prosthetic valves.9 The majority (n = 213, 89%) of the
patients participated in a randomized trial and received either
a mechanical prosthetic valve (St Jude Medical Inc, St Paul,
Minn, n = 102, or Omnicarbon, Medical Inc, Inver Grove
Heights, Minn, n = 63) or a bioprosthesis (Biocor Industria e
Pesquisas Ltd, Belo Horizonte, Brazil, n = 74). Patients with
a narrow aortic root (valve size 19 or 21 mm) received either
a St Jude Medical or Omnicarbon mechanical prosthesis.
Patients with severe aortic regurgitation (n = 52), concomitant
mitral surgery (n = 7), a small bioprosthesis (valve size 21
mm, n = 3), a large prosthesis (valve size 29 mm, n = 2), and
prosthesis obstruction (n = 1) were excluded. The remaining
population comprised 174 patients (mechanical = 122, bio-
logic = 52). Inasmuch as 19 patients died, 16 patients
declined further participation, and 2 were not evaluated
before the operation, altogether 137 patients (mechanical
valves = 95, biologic valves = 42) were investigated both
before and approximately 2 years after the operation. At the
late follow-up the patients received a questionnaire, they were
interviewed about preoperative and late postoperative symp-
toms (dyspnea and angina), and their functional status was
classified according to the New York Heart Association
(NYHA). Informed consent was obtained from all patients
and the study was approved by the Human Ethics Committee
at Sahlgrenska University Hospital. 
The St Jude Medical Standard Valve is a bileaflet pyrolytic
carbon valve with an 85-degree leaflet angle in the open posi-
tion. The monoleaflet Omnicarbon valve consists of pyrolytic
carbon with a maximum opening angle of 80 degrees. The
Biocor valve used in this study is a stented, glutaraldehyde-
preserved porcine bioprosthesis. The Biocor valve design
allows both intra-annular and supra-annular insertion, but dur-
ing the study period only the intra-annular position was used. 
M-mode and 2-dimensional echocardiography. Echo-
cardiography was performed with an Acuson 128 or 128XP
Computed Sonograph (Acuson, Mountain View, Calif) or a
Vingmed CFM 750 device (Vingmed Sound AS, Horten,
Norway, 17 investigations). Both M-mode recordings and off-
line measurements were guided by the 2-dimensional image.
M-mode measurements were made according to the recom-
mendations of the American Society of Echocardiogra-
phy.10 The ejection fraction was calculated according to
Teichholz and associates11 and the LV mass by means of the
cube formula.12
Doppler measurements. Blood flow velocity in the LV
outflow tract was estimated by pulsed wave Doppler from an
apical 4-chamber view (sample size of 5 mm). Mitral flow
was recorded between the mitral leaflets in the 4-chamber
view. From the mitral velocity tracings (paper speed 100
mm/s), early flow velocity (E), deceleration time of E wave,
and peak velocity during atrial systole (A) were measured.
Pulmonary venous flow velocities were obtained from the
upper right pulmonary vein (paper speed 50 mm/s). Peak
velocities during systole (S) and diastole (D) were measured.
Continuous wave Doppler signals were recorded from multi-
ple windows by a 2-MHZ non-imaging probe. 
The stroke volume was calculated as the product of the
cross-sectional area of the LV outflow tract (CSA) and the
velocity time integral (VTILVOT). The cardiac index was
calculated as the product of heart rate and stroke volume
divided by the body surface area. Pressure gradients were cal-
culated according to the simplified Bernoulli equation
(Doppler pressure gradient = 4 · [peak velocity]2). The mean
gradients were calculated from off-line planimetry of the con-
tinuous wave Doppler recordings. The effective orifice area
was calculated according to the integral method: Effective
orifice area = CSA · (VTILVOT/VTImax).13
Normal limits and patterns describing diastolic func-
tion. The diastolic function was evaluated by integrating
mitral flow and pulmonary venous information. Three differ-
ent filling patterns were described: type A, normal diastolic
function; type B, normal mitral E/A ratio and S/D ratio, mild-
to-moderate diastolic dysfunction with normal or slightly
increased LV filling pressure, decreased E/A ratio, and nor-
mal S/D; and type C, severe diastolic dysfunction with
increased LV filling pressure, decreased S/D ratio, and nor-
mal or increased E/A ratio. The normal limits for mitral flow
E/A and pulmonary venous flow S/D ratios were defined as
being within 90% of the normal distribution (mean ± 1.65
standard deviation). The healthy control group consisted of
33 men and 27 women without hypertension or diabetes mel-
litus, with a normal resting electrocardiogram, and without
any history of heart disease. The mitral and pulmonary
venous flow parameters describing diastolic function are age
dependent.14 We therefore made a separate determination of
the normal limits for mitral flow E/A ratio and pulmonary
venous S/D ratio for patients less than 60 years old and 60
years of age or older. 
Statistics. Continuous variables are summarized with the
use of mean and standard deviation. Categoric variables are
summarized with the use of absolute and relative frequencies.
Differences between investigations were evaluated by means
of a paired Student t test. Proportions between patient groups
were tested by use of a c 2 test, and changes in proportions
within a group of patients were tested by the Wilcoxon signed
rank test. The results for the primary efficacy variables are
presented together with 95% confidence intervals (CI). No
adjustments for multiple statistical testing were performed.
The relationship between prosthesis size and Doppler
echocardiographic variables was evaluated by simple linear
regression analysis calculating R2 (Pearson’s coefficient of
variation). A multiple regression analysis was performed to
identify factors important to LV mass reduction and mean
Doppler gradient across the prosthesis. The variables tested
for LV mass reduction were age, sex, severity of aortic steno-
sis (mean pressure gradient), blood pressure, and prosthesis
characteristics (type, size, mean prosthesis gradient, and
effective orifice area). In the case of the mean Doppler gradi-
ent across the prosthesis, the variables tested were body size
(body surface area), flow through the prosthesis (cardiac
index), and prosthesis characteristics (type and size).
Interobserver and intraobserver variability. At our lab-
oratory, the interobserver/intraobserver variability, defined as
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the mean value of difference/mean value of measurements in
percent, is as follows; for 2-dimensionally guided M-mode
echocardiography (LV diameter in diastole), 1%/1%; Doppler
measurements (mitral early deceleration time), 5%/12%; cal-
culations based on Doppler measurements (E/A ratio),
9%/8%; calculations based on 2-dimensional and Doppler
measurements (effective orifice area), 2%/1%; and LV mass
calculations based on M-mode echocardiography, 11%/4%.
Results
Clinical characteristics. Patients who received a
mechanical prosthesis were investigated 27 ± 6.6
months after the operation, and patients with a biologic
prosthesis were investigated 25 ± 5.2 months after the
operation (P = .105). The female dominance in the
mechanical valve group was due to the fact that only
women received 19-mm valves and 92% of the patients
with size 21-mm prostheses were women (Table I). Of
32 patients with a prosthetic valve size 19 or 21 mm, 30
were older than 60 years of age. Patients with mechan-
ical prostheses were comparable with patients with bio-
prostheses in terms of severity of aortic valve disease.
The patients who were not alive 2 years after the
operation were older than the study subjects (75 ± 5.7
vs 70 ± 8.2 years; P = .01). The cause of death was
heart failure or infarction in all of those (6/19, 46%)
who had an early death (≤30 days after valve replace-
ment), whereas the cause was noncardiac in 46% of
those who died later (13/19). The patients who were
not alive at follow-up and the patients who did not want
to participate had similar preoperative Doppler
echocardiographic findings (stenosis severity, ejection
fraction, LV mass, and diastolic function parameters)
compared with the study subjects.
Influence of aortic valve replacement. The preop-
erative functional status assessed according to the
NYHA classification was comparable for patients with
mechanical valves and patients with biologic valves.
Dyspnea was the dominant preoperative symptom. The
percentage of patients with severe dyspnea (NYHA
classes III and IV) decreased from 53% to 13% (P =
.001) and with angina from 31% to 7% (P = .001).
There was no difference in the effect of valve replace-
ment between mechanical and bioprosthetic valves.
LV diastolic and systolic diameter indexed to body
surface area decreased and the ejection fraction and
cardiac index increased (Tables IIa and IIb). The ejec-
tion fraction increased from 62% (95% CI: 59.7%-
64.7%) to 65% (95% CI: 62.2%-67%) (P = .002) in the
postoperative period, whereas the cardiac index
increased from 2.6 L/min per square meter (95% CI:
2.48-2.72 L/min per square meter) to 3.1 L/min per
square meter (95% CI: 2.94-3.26 L/min per square
meter) (P = .001). The proportion of patients who had
an increase in ejection fraction was 64%, whereas the
figure for cardiac index was 72%. Fig 1 shows that the
effects of aortic valve replacement on ejection fraction
were most pronounced among patients with a severely
reduced ejection fraction before the operation. The pro-
portion of patients with normal diastolic function (type
A) assessed from mitral and pulmonary venous veloci-
ty recordings increased because of a reduction in the
number of patients with mild-to-moderate diastolic
dysfunction (type B) (Fig 2). There were no statistical-
ly significant differences between mechanical and bio-
logic valves. After aortic valve replacement, the LV
mass index decreased 42.4 g (95% CI: 35-50 g), which
constitutes a reduction of 24% (95% CI: 20%-28%).
Influence of valve size and type. For both mechani-
cal and biologic prostheses, the mean Doppler gradients
decreased and the effective orifice area and effective
orifice area index increased with increasing valve size
(Table III). Fig 3 shows that the strength of the relation-
ship (slope) to valve size was strongest for effective ori-
fice area and lower for mean gradient. Prosthetic valve
size could explain 41% (mechanical) and 50% (biolog-
ic) of the variability in effective orifice area, whereas
the corresponding percentages for mean Doppler gradi-
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Table I. Preoperative and postoperative clinical characteristics of patients receiving a mechanical (St Jude
Medical, n = 67, Omnicarbon, n = 28) or a biologic (Biocor, n = 42) prosthetic valve in the aortic position
Mechanical (n = 95) Biologic (n = 42) P value
Female (%) 54 36 .052
CABG (%) 27 36 .325
Age at operation (y) 70 ± 7.8 69 ± 9.2 >.40
Mean pressure gradient (mm Hg) 61 ± 19.4 61 ± 17.2 >.40
Aortic valve area index (cm2/m2) 0.35 ± 0.10 0.36 ± 0.12 >.40
Distribution of valve sizes: 19 mm, 21 mm, 7, 26, 34, 27, 5 0, 0, 40, 36, 24 .001
23 mm, 25 mm, 27 mm (%)
P values are given for comparison of mechanical and biologic valves. Values are mean ± standard deviation. CABG, Coronary artery bypass grafting.
ents were 18% (mechanical) and 19% (biologic). Table
IV shows the results of a multiple regression analysis of
factors important for LV mass index regression and
mean prosthetic Doppler gradient. The mean pressure
gradient in the native aortic valve, prosthetic valve type,
and size played a statistically significant part in explain-
ing LV mass index regression, whereas prosthesis mean
gradient and effective orifice area did not. The LV mass
index regression in mechanical valves was more pro-
nounced than in biologic valves, with an overall differ-
ence of 21.7 g (95% CI: 37.1-6.4 g) between mechani-
cal and biologic valves of the same size. The effect on
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Table IIa. Preoperative and postoperative echocardiographic data related to LV systolic and diastolic function in
mechanical prosthetic valves
Preoperative n Postoperative n Mean difference n P value
LVd index (cm/m2) 2.91 ± 0.35 61 2.79 ± 0.44 76 0.15 ± 0.37 57 .004
(2.82 to 3.00) (2.69 to 2.89) (0.05 to 0.25)
LVs index (cm/m2) 1.91 ± 0.43 61 1.78 ± 0.48 76 0.18 ± 0.40 57 .002
(1.80 to 2.02) (1.67 to 1.89) (0.07 to 0.28)
Ejection fraction (%) 62.5 ± 13.3 61 65.9 ± 11.3 74 –3.9 ± 12.4 56 .019
(59.2 to 65.8) (63.3 to 68.5) (–7.2 to –0.73)
Cardiac index (L/min/m2) 2.55 ± 0.76 91 3.04 ± 0.88 90 –0.46 ± 0.94 87 .0001
(2.40 to 2.70) (2.86 to 3.22) (–0.65 to –0.26)
E/A ratio 1.0 ± 0.74 80 1.02 ± 0.31 75 –0.057 ± 0.65 72 >.40
(0.84 to 1.16) (0.98 to 1.06) (–0.21 to 0.09)
E dec (ms) 239 ± 99.5 70 238 ± 72.5 72 16 ± 99 56 .209
(215 to 262) (221 to 255) (–9 to 43)
S velocity (cm/s) 55 ± 16 69 56 ± 14) 60 0.02 ± 0.16 48 >.40
(51 to 59) (52 to 60) (–0.03 to 0.06)
D velocity (cm/s) 45 ± 16 69 47 ± 13 60 –0.02 ± 0.14 48 .163
(41 to 49) (44 to 50) (–0.04 to 0.01)
S/D ratio 1.41 ± 0.64 69 1.26 ± 0.33 60 0.22 ± 0.56 48 .0095
(1.26 to 1.56) (1.18 to 1.34) (0.06 to 0.38)
Mean ± standard deviation (95% confidence interval). LVd index, LV diameter in diastole indexed to body surface area; LVs index, LV diameter in systole indexed to
body surface area; E/A ratio, ratio between early (E) and late (A) peak mitral velocity; E dec, E wave deceleration time; S velocity, peak velocity in pulmonary vein
during systole; D velocity, peak velocity in pulmonary vein during diastole.
Table IIb. Preoperative and postoperative echocardiographic data related to LV systolic and diastolic function in
biologic prosthetic valves
Preoperative n Postoperative n Mean difference n P value
LVd index (cm/m2) 2.92 ± 0.34 33 2.74 ± 0.31 35 0.21 ± 0.29 28 .0007
(2.80 to 3.04) (2.64 to 2.84) (0.10 to 0.32)
LVs index (cm/m2) 1.95 ± 0.46 33 1.80 ± 0.42 35 0.23 ± 0.28 28 .0001
(1.79 to 2.11) (1.66 to 1.94) (0.13 to 0.33)
Ejection fraction (%) 60.3 ± 14.0 33 61.6 ± 14.7 33 –4.4 ± 10.3 26 .038
(55.5 to 65.1) (56.6 to 67.3) (–8.4 to –0.4)
Cardiac index (L/min/m2) 2.63 ± 0.91 41 3.14 ± 0.86 42 0.53 ± 1.03 41 .0021
(2.35 to 2.91) (2.88 to 3.40) (–0.85 to –0.21)
E/A ratio 1.0 ± 0.57 32 0.94 ± 0.3 34 0.04 ± 0.58 28 >.40
(0.80 to 1.20) (0.84 to 1.04) (–0.18 to 0.26)
E dec (ms) 268 ± 120 31 241 ± 68 33 35 ± 120 27 .146
(226 to 310) (218 to 264) (–11 to 79)
S velocity(cm/s) 56 ± 16 30 62 ± 13 25 –0.05 ± 0.13 20 .127
(50 to 62) (57 to 67) (–0.10 to 0.01)
D velocity (cm/s) 47 ± 16 30 52 ± 13 25 –0.08 ± 0.15 20 .027
(41 to 53) (47 to 57) (0.15 to 0.015)
S/D ratio 1.36 ± 0.58 30 1.29 ± 0.53 25 0.16 ± 0.49 20 .154
(1.15 to 1.57) (1.08 to 1.50) (–0.05 to 0.37)
Mean ± standard deviation (95% confidence interval). LVd index, LV diameter in diastole indexed to body surface area; LVs index, LV diameter in systole indexed to
body surface area; E/A ratio, ratio between early (E) and late (A) peak mitral velocity; E dec, E wave deceleration time; S velocity, peak velocity in pulmonary vein
during systole; D velocity, peak velocity in pulmonary vein during diastole.
LV mass index regression produced by increasing the
valve size by 2 mm was 7.4 g (95% CI: 0.5-14.7 g). The
multiple regression equation could explain 27% of the
observed variability in LV mass index regression.
Variables important to the mean prosthetic Doppler gra-
dient were prosthetic size and type, cardiac index, and
body surface area. Mechanical valves had lower mean
Doppler gradients, with an overall difference of 4 mm
Hg (95% CI: 2-6.1 mm Hg) compared with biologic
valves of the same size. The effect on mean prosthetic
Doppler gradient produced by increasing the valve size
by 2 mm was 4.2 mm Hg (95% CI: 5.4-3.0 mm Hg).
The multiple regression equation could explain 36% of
the observed variability in mean prosthetic Doppler gra-
dient. Mechanical valves size 23 mm had a better hemo-
dynamic performance with a lower mean pressure
decrease (P = .014) and a larger effective orifice area
index (P = .014) stented biologic valves of the same
size. Mechanical valve size 21 mm was comparable
with bioprosthesis size 23 mm.
Discussion
Influence of aortic valve replacement. We found
that aortic valve replacement produced effects such as
regression in LV mass index and improved systolic and
diastolic function. The magnitude of LV mass index
regression in our study (24%) was comparable with
that noted by other investigators (20%-34%).5-7,15
Diastolic function improved, but 2 years after the
operation a large proportion of the patients (34%) still
showed signs of disturbed filling properties and
increased LV mass. This lack of normalization might
be an expression of patient-prosthesis mismatch with
an important LV pressure load. However, the patients
were investigated 26 months after the operation (range
16-60 months), and this may be an insufficient period
in which to achieve a regression in LV mass and dias-
tolic dysfunction. Using hemodynamic and endomy-
ocardial biopsy studies, Monrad,7 Krayenbuehl,16 and
their associates have shown that the process of
myocardial remodeling occurs over many years. They
found that for patients with aortic stenosis undergoing
aortic valve replacement, the LV mass index was
reduced from 114 g/m2 at an intermediate postopera-
tive investigation (1.6 ± 0.5 years) to 97 g/m2 at a late
investigation (8.1 ± 2.9 years). Their studies myocar-
dial structure revealed that the regression in LV mass at
the intermediate stage after aortic valve replacement
was due to a decrease in myocardial cellular hypertro-
phy with an increase in relative interstitial fibrosis.16 At
the late investigation, the LV fibrous content also
decreased. When the passive diastolic properties were
determined at the intermediate stage, the patients had
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Fig 1. Effect of aortic valve replacement on ejection fraction
(n = 83).
Fig 2. Effect of aortic valve replacement on diastolic func-
tion. Type A, Normal diastolic function; type B, mild to mod-
erate diastolic dysfunction with normal or slightly increased
LV filling pressure; type C, severe diastolic dysfunction with
increased LV filling pressure.
increased myocardial stiffness, which normalized at a late
stage after aortic valve replacement.17,18 From these stud-
ies, we can expect a further reduction in LV mass with
less disturbed diastolic function in our patient group. 
In our study, we found an improvement in systolic
function with a decrease in diastolic and systolic
dimensions and an increase in ejection fraction. The
increase in ejection fraction was more than an adjust-
ment to reduced LV volumes, inasmuch as the cardiac
index was also increased. This finding is in accordance
with those of other investigators, and improved systolic
function has been shown to occur during the operation,
immediately after aortic valve replacement.7,19 We
observed a marked improvement in cardiac index and
ejection fraction among patients with the most severe
preoperative dysfunction, which implies that a decrease
in preoperative ejection fraction caused by excess after-
load does not preclude a postoperative improvement in
LV function. Systolic dysfunction in patients with aor-
tic stenosis is therefore due predominantly to afterload
excess rather than to intrinsic myocardial damage.
Influence of prosthetic valve type and size. We
found higher pressure gradients in biologic valves than
in mechanical valves. This implies that the LV pressure
is higher in patients with biologic valves, which could
explain a less pronounced regression in LV mass index.
Our findings differ from those of others, for LV mass
index decreased in patients with 19 and 21 mm
valves.5,6 González-Juanatey,5 Sim,6 and their col-
leagues both included patients with small biologic
valves (8/12 and 8/10, respectively, receiving valve size
19 mm), and they found no statistically significant
regression in LV mass index in these groups of patients.
In the present study, patients were investigated
prospectively and randomized to either a mechanical or
a biologic prosthesis with the important exception of
those patients with a small aortic root (size 19 or 21
mm), who all received a mechanical valve. This selec-
tion policy probably has influenced our results. The
less pronounced regression of LV mass index reported
by others could therefore be due to valve type rather
than valve size.
Prosthesis-patient mismatch. In some patients with
a large body surface area relative to aortic root dimen-
sions, or in physically active individuals, can a small
prosthetic valve cause an obstruction of hemodynamic
importance?20,21 This prosthesis-patient mismatch has
been claimed to be present at an effective orifice area
index of 0.85 cm2/m2 or less.22 We found effective ori-
fice area indices indicating prosthesis-patient mismatch
in the majority of patients receiving valve sizes of 23
mm or smaller. It was therefore unexpected to find only
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Fig 3. Left, Relationship between prosthesis size and effective orifice area. Linear regression for mechanical
valves (solid line, n = 92, y = 0.15x – 1.8, standard error of the slope = 0.02, r = 0.63, P = .001) and biologic
valves (dashed line, n = 41, y = 0.22x – 3.8, standard error of the slope = 0.035, r = 0.71, P = .001). Right,
Relationship between prosthesis size and mean prosthetic Doppler gradient. Linear regression for mechanical
valves (solid line, n = 95, y = 45.8 – 1.3x, standard error of the slope = 0.30, r = 0.41, P = .001) and biologic
valves (dashed line, n = 42, y = 58.7 – 1.7x, standard error of the slope = 0.54, r = 0.44, P = .004).
a weak relationship between prosthetic valve size and
regression of LV mass index. Limitations in the Doppler
echocardiographic method could cause some underesti-
mation of the effective orifice area. However, this find-
ing might also illustrate a limitation in the effective ori-
fice area index as a measure of prosthetic function.
There is a pronounced normal variation in cardiac
index, and individuals with an identical effective orifice
area index may have quite different transprosthetic flow
and pressure gradients. Most patients receiving small
prosthetic valves are elderly women, and it is therefore
possible that a low physical activity level in these
patients further helps to reduce the pressure burden.
Our findings of a reduction in LV mass index in
patients with small aortic valve sizes should not be
interpreted as an argument that prosthesis-patient mis-
match is not a problem. The possibility of obstruction
after valve replacement should always be kept in mind
when there is a discrepancy between aortic root diam-
eter and body surface area or if the patient is physical-
ly active. We have previously shown that it is possible
to use a preoperative echocardiographic measurement
of the LV outflow tract to identify most of the patients
who will receive a small prosthesis.23 It is an obvious
advantage to know in advance that a patient is likely to
receive a small prosthesis, because this will facilitate
alternatives such as homograft insertion, enlargement
of the aortic root, or supra-annular implantation. 
Study limitations. In the present study we investi-
gated patients approximately 2 years after aortic valve
replacement. The patients who did not want to partici-
pate (n = 16) in the late follow-up and those who died
of cardiac related causes (n = 13) were preoperatively
similar to the study subjects in terms of severity of aor-
tic stenosis, LV mass, and systolic and diastolic func-
tion parameters. Therefore it is not likely that our
results are importantly biased by this loss of patients. 
Another possible cause of bias in the present study is
the fact that we do not at our institution use small stented
biologic valves (size 19 or 21 mm) to avoid prosthesis-
patient mismatch. It is conceivable that including these
valves would have made the overall differences between
mechanical and biologic valves more pronounced in
terms of prosthesis gradients and LV mass regression. 
In this study, we compared pressure gradients and
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Table III. Clinical and echocardiographic data related to valve type and size
Size 23 Size 25 Size 27Size 19: Size 21:
Mechanical Mechanical Mechanical Biologic Mechanical Biologic Mechanical Biologic 
(n = 7) (n = 25) (n = 25) (n = 17) (n = 26) (n = 15) (n = 5) (n = 10)
BSA (m2) 1.64 ± 0.12 1.74 ± 0.20 1.82 ± 0.17 1.76 ± 0.13 1.91 ± 0.17 1.83 ± 0.15 1.93 ± 0.12 2.07 ± 0.13
Mean gradient (mm Hg) 20 ± 6.8 18 ± 6.0 16 ± 5.7 21 ± 6.9 13 ± 6.7 15 ± 4.3 10 ± 2.8 15 ± 3.6
EOA index (cm2/m2) 0.76 ± 0.17 0.8 ± 0.15 0.87 ± 0.20 0.74 ± 0.14 1.1 ± 0.27 0.9 ± 0.20 1.2 ± 0.28 1.1 ± 0.24
Preop LVMI (g/m2) 144 ± 21.0 156 ± 40.9 167 ± 39.5 176 ± 35.6 147 ± 25.5 153 ± 31.0 209 ± 41.3 174 ± 32.6
(128-152) (135-177) (149-185) (155-197) (134-160) (134-172) (173-245) (148-200)
Postop LVMI (g/m2) 104 ± 17.6 123 ± 44.4 127 ± 27.1 129 ± 26.9 119 ± 50.8 127 ± 38.9 126 ± 24.7 131 ± 24.4
(89-119)* (104-142)‡ (116-138)‡ (114-144)† (97-141)‡ (105-149) (104-148)† (114-148)†
D LVMI (g/m2) 40 ± 26.4 43 ± 28.1 47 ± 46.2 32 ± 25.5 44 ± 29.4 24 ± 38.8 83 ± 25.8 41 ± 16.6
D LVMI (%) 27 ± 14.6 27 ± 13.5 25 ± 21.8 18 ± 14.9 29 ± 15.8 15 ± 24.6 40 ± 7.2 24 ± 5.6
Mean ± standard deviation (95% confidence interval). BSA, Body surface area; EOA index, effective orifice area indexed to body surface area; LVMI, LV mass index.
*P < .05. 
†P < .01. 
‡P < .001 (postoperative versus preoperative values).
Table IV. Factors important for LV mass index regres-
sion (n = 80) and mean prosthetic Doppler gradient
(n = 132) analyzed by multiple regression
Variables b 95% CI P value
LVMI regression
Aortic valve mean pressure 0.76 0.42 to 1.11 .001
gradient
Prosthesis type –21.7 –37.1 to –6.2 .007
Biologic = 1
Mechanical = 0
Prosthesis size 3.7 0.26 to 7.1 .04
Mean prosthetic Doppler 
gradient
Prosthesis size –2.1 –2.7 to –1.5 .001
Cardiac index 2.4 1.4 to 3.4 .001
BSA 11.8 6.2 to 17.4 .001
Prosthesis type 4.0 2.0 to 6.1 .001
Biologic = 1
Mechanical = 0
LVMI, LV mass index (gm/m2); b, slope of regression line; BSA, body surface
area (m2).
effective orifice areas in biologic and mechanical pros-
thetic heart valves. However, several in vitro studies
reveal that valve design influences the flow velocity
profile, pressure decrease profile, and calculated orifice
area.24,25 Localized increased flow velocity and pres-
sure recovery have been shown to cause an overestima-
tion of pressure decrease and underestimation of effec-
tive orifice area. This phenomenon is probably most
pronounced in bileaflet mechanical valves,25 but it has
also been claimed to introduce errors in estimations of
pressure gradients in biologic valves.26 The pressure
decreases and calculated effective orifice area in one
prosthetic valve type are therefore not necessarily com-
parable with those found with another valve design.
The group of patients with mechanical valves consists
of two different valve types, a bileaflet valve (St Jude
Medical) and a monoleaflet valve (Omnicarbon).
However, the two valve designs do not differ in terms
of Doppler echocardiographic findings (peak velocity,
gradients, or effective orifice area).9 These limitations
in the Doppler echocardiographic assessment of pros-
thesis hemodynamics might explain some of the lack of
relation between prosthesis gradients, effective orifice
area, and LV mass regression. 
Clinical implication. We found more extensive
(approximately double) reduction in LV mass index
with mechanical prostheses than with bioprostheses of
the same size, a finding that might need consideration
in the individual choice of prosthetic valve. However,
we do not yet know whether a concomitantly possible
lower-risk reduction with a bioprosthesis is overbal-
anced by fewer vascular events.
Small biologic valves (19 and 21 mm) often result in
obstruction and are usually avoided. This implies that
many elderly female patients with narrow aortic roots
and a life expectancy that does not exceed that of a bio-
logic prosthesis receive a mechanical valve for hemo-
dynamic reasons. An alternative approach in these
elderly patients might be to insert a 23-mm biologic
valve after performing an aortic root enlargement or to
insert the prosthesis in a supra-annular position. We
found no statistically significant differences in hemo-
dynamics or LV mass index regression between 21-mm
mechanical valves and 23-mm biologic valves, and the
use of biologic valves might beneficially influence the
outcome, because it would reduce the complications
associated with anticoagulant therapy. However, this
would prolong the aortic crossclamp time in a prognos-
tically unfavorable way.27
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